Cure8 research brief
Purinergic signaling connects nerves, immune cells, epithelium, and microbiota in the gut — pathways that can influence inflammation, motility, and pain relevant to IBD. Understanding these mechanisms could point to new treatment targets.
Clinicians, researchers, and adult patients interested in IBD pathogenesis and emerging therapeutic targets
The authors synthesize preclinical and mechanistic studies showing that purinergic receptors (notably P2X7) regulate neuro-immune interactions that can drive neuroinflammation, enteric neuron loss, dysmotility, and visceral hypersensitivity.
Adenosine receptors are discussed as generally immunomodulatory and tissue-protective, but effects depend on cell type and context. The review highlights ectonucleotidases and several receptor targets as emerging therapeutic opportunities to restore intestinal function or limit chronic inflammation.
The article is a mechanistic review rather than a clinical trial or guideline. It is useful for understanding potential future drug targets and the biological rationale linking neuronal, immune, and epithelial dysfunction in IBD.
This is a mechanistic review (abstract-level summary provided). Many findings discussed are from preclinical or experimental models; clinical efficacy of purinergic-targeting therapies remains to be established.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study points to a specific gut microbe, Mediterraneibacter gnavus, that may be linked to joint inflammation in people with Crohn's disease. If confirmed, a microbial biomarker could help identify who is at risk for...
The review connects Western diet-driven metabolic shifts in the gut, immune cells, and microbiota to ulcerative colitis mechanisms and highlights metabolism-targeting therapies as a potential future avenue for treatment.
The study suggests B cells can protect against colitis through secretory IgA that reshapes the gut microbiota, a mechanism separate from known regulatory B cell cytokines. This could point to new directions for IBD...
